Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 May 18;347(9012):1374-5.
doi: 10.1016/s0140-6736(96)91013-2.

Resistance to activated protein C in an unselected population of patients with pulmonary embolism

Affiliations
Clinical Trial

Resistance to activated protein C in an unselected population of patients with pulmonary embolism

S Desmarais et al. Lancet. .

Abstract

Background: Resistance to activated protein C (APC) is the most frequent cause of inherited thrombophilia. This phenomenon has been reported in 10-50% of selected patients with venous thromboembolism, a variation that might result from different degrees of selection in different reports.

Methods: We measured the APC sensitivity ratio in 494 frozen blood samples from unselected consecutive outpatients suspected of pulmonary embolism and referred over a 30-month period to the emergency ward of the University Hospital of Geneva, the only public primary-tertiary care hospital in the region of Geneva (400,000 inhabitants).

Findings: Prevalence of resistance to APC was 5.5% (95% Cl 2.4-10.5%) (8/146) in patients with confirmed pulmonary embolism and 4.0% (2.2-6.7%) (14/348) in patients in whom the diagnosis could be ruled out (p = 0.66), giving an odds ratio of 1.36 (0.56-3.32).

Interpretation: The very different risks of venous thromboembolism in the presence of resistance to APC that have been reported in trials published so far are probably due to variable recruitment conditions. The lower prevalence observed in our totally unselected population of patients with pulmonary embolism may be more representative of the real risk with which clinicians will be confronted. Therefore, more data are needed from various populations of patients with venous thromboembolism to help decide which patients will benefit from screening for resistance to APC.

PubMed Disclaimer

Comment in